Back to Journals » Journal of Pain Research » Volume 8

Effectiveness of pregabalin for the treatment of chronic low back pain with accompanying lower limb pain (neuropathic component): a non-interventional study in Japan

Authors Taguchi T, Igarashi A, Watt S, Parsons B, Sadosky A, Nozawa K, Hayakawa K, Yoshiyama T, Ebata N, Fujii K

Received 15 May 2015

Accepted for publication 19 June 2015

Published 5 August 2015 Volume 2015:8 Pages 487—497

DOI https://doi.org/10.2147/JPR.S88642

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Kerui Gong

Peer reviewer comments 5

Editor who approved publication: Dr Michael Schatman

Toshihiko Taguchi,1 Ataru Igarashi,2 Stephen Watt,3 Bruce Parsons,3 Alesia Sadosky,3 Kazutaka Nozawa,4 Kazuhiro Hayakawa,4 Tamotsu Yoshiyama,4 Nozomi Ebata,4 Koichi Fujii4

1Department of Orthopaedic Surgery, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan; 2Department of Drug Policy and Management, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan; 3Pfizer Inc., New York, NY, USA; 4Pfizer Japan, Inc., Tokyo, Japan

Objective: To evaluate the impact of pregabalin on sleep, pain, function, and health status in patients with chronic low back pain with accompanying neuropathic pain (CLBP-NeP) under routine clinical practice.
Methods: This prospective, non-interventional, observational study enrolled Japanese adults (≥18 years) with CLBP-NeP of duration ≥3 months and severity ≥5 on a numerical rating scale (0= no pain, 10= worst possible pain). Treatment was 8 weeks with pregabalin (n=157) or usual care alone (n=174); choice of treatment was determined by the physician. The primary efficacy outcome was change from baseline to 8 weeks in pain-related interference with sleep, assessed using the Pain-Related Sleep Interference Scale (PRSIS; 0= did not interfere with sleep, 10= completely interferes with sleep). Secondary endpoints were changes in PRSIS at week 4, and changes at weeks 4 and 8 in pain (numerical rating scale), function (Roland-Morris Disability Questionnaire), and quality of life (EuroQol 5D-5L); global assessments of change were evaluated from the clinician and patient perspectives at the final visit.
Results: Demographic characteristics were similar between cohorts, but clinical characteristics suggested greater disease severity in the pregabalin group including a higher mean (standard deviation) pain score, 6.3 (1.2) versus 5.8 (1.1) (P<0.001). For the primary endpoint, pregabalin resulted in significantly greater improvements in PRSIS at week 8, least-squares mean changes of -1.3 versus -0.4 for usual care (P<0.001); pregabalin also resulted in greater PRSIS improvement at week 4 (P=0.012). Relative to usual care at week 8, pregabalin improved pain and function (both P<0.001), and showed global improvements since beginning study medication (P<0.001). Pregabalin was well tolerated.
Conclusion: In clinical practice in patients with CLBP-NeP, pregabalin showed significantly greater improvements in pain-related interference with sleep relative to usual care. In addition, pregabalin significantly improved pain, function, and health status, suggesting the benefits of pregabalin for overall health and well-being relative to usual care in these patients. (Clinicaltrials.gov identifier NCT02273908).

Keywords:
pregabalin, usual care, chronic low back pain, neuropathic pain, non-interventional study, sleep

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Characterizing individual painDETECT symptoms by average pain severity

Sadosky A, Koduru V, Bienen EJ, Cappelleri JC

ClinicoEconomics and Outcomes Research 2016, 8:361-366

Published Date: 26 July 2016

Characterizing neuropathic pain profiles: enriching interpretation of painDETECT

Cappelleri JC, Koduru V, Bienen EJ, Sadosky A

Patient Related Outcome Measures 2016, 7:93-99

Published Date: 5 July 2016

Cost-effectiveness analysis of pregabalin for treatment of chronic low back pain in patients with accompanying lower limb pain (neuropathic component) in Japan

Igarashi A, Akazawa M, Murata T, Taguchi T, Sadosky A, Ebata N, Willke R, Fujii K, Doherty J, Kobayashi M

ClinicoEconomics and Outcomes Research 2015, 7:505-520

Published Date: 7 October 2015

A cross-sectional study examining the psychometric properties of the painDETECT measure in neuropathic pain

Cappelleri JC, Koduru V, Bienen EJ, Sadosky A

Journal of Pain Research 2015, 8:159-167

Published Date: 15 April 2015

Measurement properties of painDETECT by average pain severity

Cappelleri JC, Bienen EJ, Koduru V, Sadosky A

ClinicoEconomics and Outcomes Research 2014, 6:497-504

Published Date: 6 November 2014

Pain severity and the economic burden of neuropathic pain in the United States: BEAT Neuropathic Pain Observational Study

Schaefer C, Sadosky A, Mann R, Daniel S, Parsons B, Tuchman M, Anschel A, Stacey BR, Nalamachu S, Nieshoff E

ClinicoEconomics and Outcomes Research 2014, 6:483-496

Published Date: 29 October 2014

Economic and humanistic burden of post-trauma and post-surgical neuropathic pain among adults in the United States

Parsons B, Schaefer C, Mann R, Sadosky A, Daniel S, Nalamachu S, Stacey BR, Nieshoff EC, Tuchman M, Anschel A

Journal of Pain Research 2013, 6:459-469

Published Date: 17 June 2013

Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis

Srivastava K, Arora A, Kataria A, Cappelleri JC, Sadosky A, Peterson AM

Patient Preference and Adherence 2013, 7:419-434

Published Date: 20 May 2013

Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US: results from a retrospective chart review and cross-sectional survey

Sadosky A, Schaefer C, Mann R, Bergstrom F, Baik R, Parsons B, Nalamachu S, Nieshoff E, Stacey BR, Anschel A, Tuchman M

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2013, 6:79-92

Published Date: 8 February 2013

Association of patient-rated severity with other outcomes in patients with painful diabetic peripheral neuropathy

Taylor-Stokes G, Pike J, Sadosky A, Chandran A, Toelle T

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2011, 4:401-408

Published Date: 5 December 2011

Readers of this article also read:

Hematuria following Botox treatment for upper limb spasticity: a case report

Lo TC, Yeung ST, Lee S, Chang EY

Journal of Pain Research 2015, 8:619-622

Published Date: 14 September 2015

Different measures, different outcomes? Survey into the effectiveness of chronic pain clinics in a London tertiary referral center

Shah S, Ho AC, Kuehler BM, Childs SR, Towlerton G, Goodall ID, Bantel C

Journal of Pain Research 2015, 8:477-486

Published Date: 5 August 2015

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010